VIA
ALNY icon

Vident Investment Advisory’s Alnylam Pharmaceuticals ALNY Stock Holding History

Vident Investment Advisory’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-1,144
Closed -$217K – 49
2023
Q2 		$217K Buy
+1,144
New +$227K 0.01% 1025
2022
Q2 		– Sell
-12,161
Closed -$1.98M – 1274
2022
Q1 		$1.98M Buy
12,161
+5,136
+73% +$782K 0.05% 457
2021
Q4 		$1.19M Sell
7,025
-4,255
-38% -$791K 0.03% 643
2021
Q3 		$2.13M Buy
11,280
+889
+9% +$167K 0.06% 372
2021
Q2 		$1.76M Sell
10,391
-1,206
-10% -$177K 0.05% 460
2021
Q1 		$1.64M Buy
11,597
+651
+6% +$98K 0.06% 467
2020
Q4 		$1.42M Buy
10,946
+873
+9% +$117K 0.06% 427
2020
Q3 		$1.47M Sell
10,073
-289
-3% -$41.1K 0.07% 374
2020
Q2 		$1.53M Buy
10,362
+7,603
+276% +$1.02M 0.08% 302
2020
Q1 		$300K Buy
2,759
+366
+15% +$42.2K 0.02% 684
2019
Q4 		$276K Sell
2,393
-1,756
-42% -$175K 0.02% 649
2019
Q3 		$334K Sell
4,149
-1,321
-24% -$105K 0.03% 422
2019
Q2 		$397K Sell
5,470
-3,422
-38% -$263K 0.03% 396
2019
Q1 		$831K Buy
8,892
+1,528
+21% +$128K 0.04% 450
2018
Q4 		$537K Sell
7,364
-170
-2% -$13.1K 0.03% 564
2018
Q3 		$659K Sell
7,534
-89
-1% -$8.95K 0.03% 595
2018
Q2 		$751K Buy
7,623
+3,157
+71% +$313K 0.03% 510
2018
Q1 		$429K Buy
4,466
+2,400
+116% +$309K 0.02% 683
2017
Q4 		$262K Buy
+2,066
New +$260K 0.01% 722

Other funds holding ALNY

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Vident Investment Advisory's ALNY Position: Q3 2023 in Review

Vident Investment Advisory sold out of Alnylam Pharmaceuticals (ALNY) in Q3 2023, closing a stake of 1,144 shares — an estimated $217K sold.

Vident Investment Advisory first reported a position in ALNY in Q4 2017 and held it in 19 quarters. The position peaked at $2.13M in Q3 2021. 453 funds tracked by Wall St. Rank hold ALNY as of Q3 2023.

  • Vident Investment Advisory reported no remaining Alnylam Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
  • Vident Investment Advisory sold 1,144 Alnylam Pharmaceuticals shares in Q3 2023, an estimated $217K.
  • Vident Investment Advisory first reported a position in Alnylam Pharmaceuticals in Q4 2017 and held it in 19 quarters.
  • Vident Investment Advisory's Alnylam Pharmaceuticals position peaked at $2.13M in Q3 2021.
  • 453 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q3 2023.

Based on Vident Investment Advisory's 13F filing for Q3 2023.